Monte Rosa Therapeutics Inc (GLUE) - Total Liabilities
Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has total liabilities worth $214.00 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Monte Rosa Therapeutics Inc generate cash to assess how effectively this company generates cash.
Monte Rosa Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Monte Rosa Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Monte Rosa Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Monte Rosa Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
China | CN¥-1.28 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥2.54 Billion |
|
Power HF Co Ltd
SHG:605100
|
China | CN¥455.28 Million |
|
IRSA Inversiones y Representaciones SA
BA:IRSA
|
Argentina | AR$2.22 Trillion |
|
Hna-Caissa Travel Group Co Ltd
SHE:000796
|
China | CN¥967.96 Million |
|
Keystone Reit Ltd
TA:KSTN
|
Israel | ILA1.91 Billion |
|
Advantage Oil & Gas Ltd.
TO:AAV
|
Canada | CA$1.35 Billion |
|
Shanghai Prisemi Electronics Co Ltd
SHG:688230
|
China | CN¥58.91 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Monte Rosa Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Monte Rosa Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Monte Rosa Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Monte Rosa Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Monte Rosa Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $215.80 Million | +73.32% |
| 2023-12-31 | $124.50 Million | +75.42% |
| 2022-12-31 | $70.98 Million | +277.25% |
| 2021-12-31 | $18.81 Million | -80.82% |
| 2020-12-31 | $98.11 Million | +322.11% |
| 2019-12-31 | $23.24 Million | -- |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more